ENGN
$7.25
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene...
Recent News
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference
Executives from enGene (NASDAQ:ENGN) provided an update on the company’s detalimogene program in non-muscle invasive bladder cancer (NMIBC), discussing recent protocol changes, regulatory interactions, and commercial planning as the study advances. Protocol amendments and response-rate improvement
enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference
enGene (NASDAQ:ENGN) CEO Ron Cooper said the company’s focus is advancing its DDX platform, a proprietary non-viral gene therapy technology, with its lead program detalimogene being developed for non-muscle invasive bladder cancer (NMIBC). Speaking at a Barclays event moderated by Senior Biotech Ana
enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update
enGene (NASDAQ:ENGN) Chief Executive Officer Ron Cooper used a presentation at the Citizens Life Sciences Conference to outline the company’s approach to non-muscle invasive bladder cancer (NMIBC), emphasizing both the unmet need in the disease and the company’s view that its investigational therapy
enGene Maps BLA by End-2026, Targets 2027 Launch for Lead NMIBC Therapy at Oppenheimer Conference
enGene (NASDAQ:ENGN) Chief Executive Officer Ron Cooper outlined the company’s near-term regulatory and clinical plans for its lead program, detalimogene voraplasmid, during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference. Cooper said the company expects to provide an
Jefferies Sets a $28 PT for enGene Holdings Inc. (ENGN)
We recently published an article titled 10 Best Low Volatility Canadian Stocks to Buy. On January 30, Jefferies initiated coverage of enGene Holdings Inc. (NASDAQ:ENGN) with a Buy rating and a $28 price target, highlighting the company’s ongoing pivotal study in high-risk non-muscle invasive bladder cancer (NMIBC), with a key data update expected in the […]